Petros Pharmaceuticals, Inc.

PTPI Healthcare Drug Manufacturers Specialty & Generic

Petros Pharmaceuticals, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $5.1 million, down 12.2% from fiscal 2023.

Revenue
+299.1%
EPS
+75.0%
Free cash flow
+71.3%

Quarter to June 2026, against a year earlier

0.00 0.00 NaN
Market cap
$1.0M
P/E
0.0×
Fwd P/E
−0.3×
Dividend yield
—
F-score
4/9
Altman Z
−16.96
Beneish M
−3.26
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

— — — —
EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
2.22 2.25 1.68 1.25
Net Debt/EBITDA
6.13 13.12 4.24 3.53
Debt/Equity
0.00 0.00 0.00 0.00
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
(0.03) (0.03) (0.02) (0.02)
Book value per Share
0.08 0.10 0.04 0.01
Free Cash Flow
(1.13) (0.93) (0.78) (0.86)
Other line items

Show all line items

Columns are period end dates · fundamentals updated 26 Oct 2026